The ongoing reductions in FDA staffing, championed by the Trump administration, are prompting serious worries about the implications for public health and safety. Biotech CEOs and leaders are urgently calling on Senate representatives to restore critical FDA functions, highlighting fears that the cuts will hinder medical product reviews and food inspections. Reports indicate that these layoffs have already led to fewer medical devices reaching the public and may delay drug approvals, raising alarms about potential risks to Americans. Additionally, experts have voiced concerns that the diminished regulatory capacity could result in increased food safety issues, emphasizing the urgency of addressing funding for small biotech companies. With historical parallels drawn to past health crises, industry stakeholders warn that the consequences of these cuts could be dire unless immediate action is taken.